radotinib
Small moleculeexperimental
Radotinib (INN; trade name Supect), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib. — Wikipedia
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT01602952)
Timeline
Indications
Studied for
Mechanism of action
PDGFRA inhibitor
- Bcr/Abl fusion proteinINHIBITOR
Bcr/Abl fusion protein inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1- Mol. weight
- 530.51 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRadotinib ↗
- ChEMBLCHEMBL4297524 ↗
Also known as
- 4-methyl-n-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
- 4-methyl-n-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide hydrochloride
- iy5511
- iy5511hcl
- radotinib
- radotinib
- radotinib
- radotinib
- radotinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06461078 | Phase 1 | Aug 5, 2024 | Il-Yang Pharm. Co., Ltd., Yonsei University |
| NCT04691661 | Phase 2 | Aug 24, 2021 | Il-Yang Pharm. Co., Ltd., University of Nantes |
| NCT03722420 | Phase 3 | Dec 28, 2018 | Il-Yang Pharm. Co., Ltd. |
| NCT03459534 | Phase 3 | Jun 25, 2018 | Catholic University of Korea, Il-Yang Pharm. Co., Ltd. |
| NCT02422719 | Phase 2 | Apr 1, 2015 | University of Ulsan |
| NCT01511289 | Phase 3 | Aug 1, 2011 | Il-Yang Pharm. Co., Ltd. |
| NCT01602952 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2008 | Il-Yang Pharm. Co., Ltd. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Il-Yang Pharm. Co., Ltd. | For profit | 6 | 6 | 3 | 2008 |
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Nantes | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Ulsan | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Yonsei University | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1